NEW YORK (GenomeWeb News) — NextGen and Kemp Biotechnologies will co-market their fee-for-service offerings, NextGen said today.
UK-based NextGen is a so-called “gene-to-protein” company, whereas Kemp provides expertise in cell culture, protein expression, and protein purification services.
Under the agreement, NextGen will offer Kemp’s pure proteins for pre-clinical research.